- Home
- PULM vs AIDX Comparison
PULM vs AIDX Comparison
Compare PULM & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | AIDX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.7M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PULM | AIDX |
|---|---|---|
| Price | $1.59 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.6K | ★ 83.6K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | 34.48 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,910,000.00 | $2,045,133.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5069.93 | 16.71 |
| 52 Week Low | $1.16 | $0.40 |
| 52 Week High | $5.50 | $14.09 |
Technical Indicators
Market Signals| Indicator | PULM | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 51.42 |
| Support Level | $1.21 | $0.52 |
| Resistance Level | $1.55 | $0.57 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.73 | 87.07 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.